Evidence analysisNovember 11, 2026Health & Science
Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 9, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Evidence Dossier: Livtencity (maribavir) for Cytomegalovirus Infection in Transplant Patients
What is Established
Livtencity is an antiviral medication authorized for use in the European Union as of November 2022. Its active ingredient, maribavir, is indicated for the treatment of illness caused by cytomegalovirus (CMV) in adults who have undergone haematopoietic stem cell transplantation or organ transplantation. The medicine targets patients whose CMV infections have not responded to at least one prior CMV treatment such as ganciclovir or valganciclovir.
Cytomegalovirus is a common virus that typically causes mild or no symptoms in healthy individuals but can reactivate and cause severe illness in immunocompromised persons, such as transplant recipients. Maribavir works by inhibiting a viral enzyme, UL97 protein kinase, which is necessary for viral replication, thus preventing the virus from multiplying and spreading.
Clinical data from a principal study involving 352 adults showed that 56% of those treated with Livtencity achieved undetectable CMV levels after 8 weeks compared to 24% treated with alternative CMV therapies chosen by their physicians. The drug is administered orally at 400 mg twice daily, typically for 8 weeks, but duration can vary based on clinical response.
Commonly reported side effects include altered taste perception, nausea, diarrhea, vomiting, and fatigue. More serious but less frequent adverse events involve weight loss and increases in blood levels of immunosuppressant drugs. Importantly, Livtencity must not be co-administered with ganciclovir or valganciclovir.
What the Source Claims
The European Medicines Agency (EMA) states that Livtencity offers a more favorable efficacy and safety profile than existing treatments for refractory CMV in the specified patient population. It highlights the drug’s role as an orphan medicine, recognizing the rarity of CMV disease in transplant patients who do not respond to standard therapies.
The EMA emphasizes that Livtencity should be prescribed and managed by healthcare professionals experienced in transplant patient care. It underscores ongoing pharmacovigilance efforts to monitor safety and adverse events continually after market authorization.
What May Be Missing from the Usual Framing
The EMA’s report focuses on the clinical efficacy and safety data supporting authorization but does not extensively discuss the long-term outcomes or real-world effectiveness of Livtencity beyond the 8-week treatment window assessed in trials. There is limited public information on the variability of response across different types of organ transplants or in patients with varying levels of immune suppression.
Additionally, the nature of adverse effects related to interactions with immunosuppressants and how these are managed in clinical practice is not fully detailed. The economic aspects of Livtencity’s adoption, including cost, reimbursement, and access considerations within diverse health systems, are also not addressed in this regulatory document.
Competing Evidence or Uncertainty
Evidence presented relies heavily on a primary clinical trial that compared Livtencity with investigator-selected alternative treatments rather than a placebo or a uniformly selected comparator. This design potentially introduces variability in the comparator group’s effectiveness. Independent verification or additional clinical trials comparing Livtencity head-to-head with specific antiviral agents are not presented in the source.
There is also insufficient evidence regarding the long-term resistance profile of CMV to maribavir, and whether repeated courses of the drug may lead to reduced effectiveness. The safety profile, although described, may require further characterization in post-marketing surveillance to detect rare or delayed adverse events.
Why It Matters
For immunocompromised patients such as organ and stem cell transplant recipients, CMV infection can cause significant morbidity and mortality. Therapies effective against CMV that has become resistant to standard treatments represent an important advance in the management of this vulnerable population.
Maribavir’s distinct mechanism of action offers a treatment option where options have been limited, potentially improving clinical outcomes and quality of life. However, the nuances of balancing antiviral efficacy with maintenance of immunosuppressive therapy highlight the complexity of managing these patients and the need for specialized clinical oversight.
Understanding both benefits and limitations of Livtencity allows healthcare providers, patients, and policymakers to make informed decisions about its use within broader transplant care protocols.
What to Verify Next
- Long-term clinical outcomes related to the use of Livtencity beyond initial viral clearance, including survival and transplant rejection rates.
- Post-authorization safety data from real-world settings to understand the incidence of serious adverse events and interactions with common immunosuppressants.
- Comparative effectiveness research directly comparing Livtencity to standard antiviral drugs in various transplant populations, including pediatric and elderly patients.
- Pharmacoeconomic analyses assessing cost-effectiveness and healthcare system impact.
- Resistance monitoring data to evaluate the development of CMV strains less susceptible to maribavir.
Readers interested in further details are encouraged to consult the original source published by the European Medicines Agency for comprehensive official information.
Source & verification
Primary source: What's new · November 10, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…